Poirier D - Search Results

1

Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments.

Poirier D. Poirier D. Recent Pat Endocr Metab Immune Drug Discov. 2015;9(1):15-23. doi: 10.2174/1872214809666150201214602. Recent Pat Endocr Metab Immune Drug Discov. 2015. PMID: 25643356 Review.

2

Molecular therapy of breast cancer: progress and future directions.

Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, Zhou M. Lin SX, et al. Among authors: poirier d. Nat Rev Endocrinol. 2010 Sep;6(9):485-93. doi: 10.1038/nrendo.2010.92. Epub 2010 Jul 20. Nat Rev Endocrinol. 2010. PMID: 20644568 Review.

3

17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.

Poirier D. Poirier D. Expert Opin Ther Pat. 2010 Sep;20(9):1123-45. doi: 10.1517/13543776.2010.505604. Expert Opin Ther Pat. 2010. PMID: 20645882 Review.

4

Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.

Sang X, Han H, Poirier D, Lin SX. Sang X, et al. Among authors: poirier d. J Steroid Biochem Mol Biol. 2018 Oct;183:80-93. doi: 10.1016/j.jsbmb.2018.05.009. Epub 2018 May 24. J Steroid Biochem Mol Biol. 2018. PMID: 29803725

5

C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships.

Sam KM, Boivin RP, Tremblay MR, Auger S, Poirier D. Sam KM, et al. Among authors: poirier d. Drug Des Discov. 1998 May;15(3):157-80. Drug Des Discov. 1998. PMID: 9689499

6

Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.

Tremblay MR, Poirier D. Tremblay MR, et al. Among authors: poirier d. J Steroid Biochem Mol Biol. 1998 Aug;66(4):179-91. doi: 10.1016/s0960-0760(98)00043-0. J Steroid Biochem Mol Biol. 1998. PMID: 9744515

7

Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.

Tremblay MR, Lin SX, Poirier D. Tremblay MR, et al. Among authors: poirier d. Steroids. 2001 Nov;66(11):821-31. doi: 10.1016/s0039-128x(01)00116-7. Steroids. 2001. PMID: 11576622

8

Inhibitors of 17 beta-hydroxysteroid dehydrogenases.

Poirier D. Poirier D. Curr Med Chem. 2003 Mar;10(6):453-77. doi: 10.2174/0929867033368222. Curr Med Chem. 2003. PMID: 12570693 Review.

9

3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.

Ngatcha BT, Laplante Y, Labrie F, Luu-The V, Poirier D. Ngatcha BT, et al. Among authors: poirier d. Mol Cell Endocrinol. 2006 Mar 27;248(1-2):225-32. doi: 10.1016/j.mce.2005.10.023. Epub 2005 Dec 15. Mol Cell Endocrinol. 2006. PMID: 16359782

10

Solid-phase organic synthesis (SPOS) of modulators of estrogenic and androgenic action.

Poirier D, Maltais R. Poirier D, et al. Mini Rev Med Chem. 2006 Jan;6(1):37-52. doi: 10.2174/138955706775197802. Mini Rev Med Chem. 2006. PMID: 16457631 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page